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Abstract
Background: Emotional health disturbances are common after aneurysmal subarachnoid hemorrhage (aSAH) and
their causes are largely unexplored. Corticotropin-releasing hormone receptor 1 (CRHR1) is a key factor in stress
reactivity and development of mental health disturbances after adverse life-events.
Methods: We explore the effect of CRHR1 genotype on mental health after aSAH in a retrospective cohort study.
One hundred twenty-five patients have been assessed using EST-Q mental health questionnaire. Genotyping of
CRHR1 single nucleotide polymorphisms (SNP-s) was performed (Rs7209436, Rs110402, Rs242924).
Results: Fatigue was present in almost half of aSAH patients, depression and anxiety in one-third. There was a high
prevalence of insomnia and panic complaints. Rs110402 minor allele decreased the risk of depression (OR = 0.25,
p = 0.027 for homozygotes). Depression was present in 14% vs 41% in minor and major allele homozygotes,
respectively. Rs110402, Rs242924 and Rs7209436 minor alleles and TAT-haplotype, formed by them, were protective
against fatigue. After Bonferroni correction only the association of Rs110402 with fatigue remained statistically
significant (OR = 0.21, p = 0.006 for minor allele homozygotes). Results remained statistically significant when
adjusted for gender, admission state, age and time from aSAH. In multiple regression analysis occurrence of fatigue
was dependent on anxiety, modified Rankin score and Rs110402 genotype (R2 = 0.34, p < 0.001).
Conclusions: CRHR1 minor genotype was associated with a lower risk of fatigue and depression after aSAH.
Genetic predisposition to mental health disturbances associated with negative life-events could be a risk factor for
fatigue and depression after aSAH and selected patients might benefit from advanced counselling in the recovery
phase.
Keywords: Aneurysm, Subarachnoid haemorrhage, Fatigue, Depression, Mental health, Cortitrophin-releasing
hormone receptor-type 1, CRHR1, Gene, SNP
Background
Incidence of aneurysmal subarachnoid haemorrhage
(aSAH) is around 7.9 per 100,000 patient years [1]. Up
to 65% survive the subacute phase and two-thirds of
those patients recover to functional independence [2, 3].
Only 15% develop a focal neurological deficit or need as-
sistance in ambulation [4]. At the same time, many
aSAH patients experience emotional and cognitive prob-
lems - anxiety and depression occurs in up to half of
aSAH cases, post-traumatic stress disorder (PTSD) is re-
ported in up to a third and occasional or constant fear
of recurrent bleeding in two-thirds of patients [5, 6]. De-
crease in health-related quality of life is a well-
documented sequela of aSAH and changes in mental
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component of quality of life were recently associated
with CRHR1 genotype [3, 7].
The amount of emotional disturbances after aSAH
seems to be out of proportion to cognitive and neuro-
logical impairments and causes of these changes are
largely unexplored. Genetic predisposition might have a
role in the formation of psychological disturbances after
aSAH. The hypothalamic–pituitary–adrenal (HPA) axis
response to stress is moderated by genetic and environ-
mental factors and is implicated in pathogenesis of emo-
tional diseases [8]. Genes that regulate the function of
the stress response system are probable moderators of
the effect that adverse life events have on the develop-
ment of emotional illness [9].
Corticotropin-releasing hormone (CRH) is a key stress
mediator in the central nervous system [10]. Corticotropin-
releasing hormone receptor 1 (CRHR1) is central in activat-
ing mesolimbic and HPA responses to different types of
stress. CRHR1 genotype has been associated with mental
health disorders and response to antidepressant treatment
[11]. It has been reported to moderate the effects of stress-
ful life events on development of major depression and
moderate stress related cortisol reactivity [12, 13]. Cortisol
response to stress has been associated with depression and
anxiety symptoms [14]. An elevated cortisol response is
generally associated with major depression (MD) [15], and
a flattened cortisol response is associated with panic dis-
order and post-traumatic stress disorder (PTSD) [16].
Few genetic studies have been conducted on the topic
of neuropsychological disturbances after aSAH [16]. The
objective of current research was to characterize specific
neuropsychiatric disturbances after aSAH and explore
the influence of CRHR1 genotype on their occurrence.
Methods
We performed a retrospective cohort study of long-term
outcome of 125 surgically treated aSAH survivors. The
studied group was selected from medical records of all
patients diagnosed with aSAH (n = 467) from January
2001 to November 2013 in a university clinic (spontan-
eous ICH and other SAH causes were excluded). Selec-
tion criteria are presented in Fig. 1.
The average age at ictus was 54 years (SD = 13; range
24–82 years). The average time between initial hospital-
isation and the study was 4 years (SD = 2.8; range 1–13
years). 41% (n = 51) of the patients were studied more
than 3 years from ictus. 70% (n = 88) of the patients were
female. 78% (n = 88) of the patients had more than 10
years of education. One patient was diagnosed with de-
pression prior to aSAH based on the national database
information available from 2009. The patients were
interviewed in person with a structured questionnaire
and blood samples were gathered. All participants gave
their written informed consent and ethical approval was
received from the institutional ethics committee.
General management of patients
All aSAH patients were managed according to general
guidelines and our protocol is previously published [17].
All patients were admitted acutely and SAH was diag-
nosed by computer tomography (CT) or lumbar punc-
ture. The aneurysm was assessed by CT-angiography or
digital subtraction angiography. All patients were ini-
tially managed in a neurointensive care unit. Almost all
patients were acutely operated upon, preferably via a
pterional approach, and the aneurysms were clipped
using standard microsurgical techniques. Endovascular
procedures were preferentially performed in a separate
institution during this time. Due to this our study in-
cludes a series of clipped patients. Clinical data of the
patients and complications are presented in Table 1.
Procedure
Clinical data and Hunt and Hess grade (HH) [18], which
is a clinical grading system designed to predict prognosis
and outcome in aSAH, were recorded at ictus.
Remaining data was collected during the follow-up
evaluation, when the patients were interviewed in person
with a structured questionnaire (Additional file 1). Pa-
tient clinical recovery was evaluated according to the
modified Rankin Scale (mRS) during the clinical inter-
view [19]. Patients were also questioned about treatment
for emotional disorders after aSAH, comorbidities, edu-
cation and social living situation (living with family/
Fig. 1 Selection of patients
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someone else or alone). Emotional State Questionnaire
(EST-Q) was used to measure emotional health.
EST-Q is a well-validated self-rating scale that con-
tains scales of Depression, Anxiety, Agoraphobia-Panic,
Fatigue and Insomnia [20]. The items of EST-Q were
derived from diagnostic criteria of DSMIV and ICD-10.
Each item is rated by occurrence on a five-point scale
ranging from 0 to 4 (respectively ‘not’ and ‘all the time’).
According to the results of factor analysis, EST-Q scales
have demonstrated internal consistency of 0.69–0.88
Cronbach alpha. The participants were asked to report
how much the various problems troubled them during
the past 4 weeks. Scoring more than the cut-off point in
a specific scale shows that the scale score is in the same
magnitude as that of most patients with the given
medical condition. The cut-off points for clinically im-
portant symptomatology were ≥ 12 points for depression
and anxiety, ≥ 8 points for fatigue, ≥ 7 points for agora-
phobia–panic and ≥ 6 points for insomnia [21]. EST-Q
includes a question about frequency of ‘Recurrent
thoughts of death or suicide’. We have described the
methodology of EST-Q in more detail previously [17].
The data was compared with an age and gender matched
general population of 3923 subjects (obtained from the
6434 respondents of a National Health Interview
Survey).
Genotyping
The genomic DNA was extracted from venous blood
samples in 4 ml EDTA containing vaccuettes by using
the standard salting-out method. The EDTA tubes were
stored at -20C until DNA extraction. Isolated DNA was
dissolved in Tris-EDTA (TE) buffer. The purity and con-
centrations of the DNA were measured by a spectropho-
tometer (NanoDrop, ND-1000). The gDNA samples
were aliquotted and stored at -80C until usage. Genotyp-
ing of marker single nucleotide polymorphisms (SNP)
Rs7209436, Rs110402, Rs242924 and Rs242939 was car-
ried out by using TaqMan SNP Genotyping Assay (Ap-
plied Biosystems, Foster City, CA, USA), which is a
multiplex endpoint assay that detects variants of a single
nucleic acid sequence. PCR reactions were run on the
ViiA7 instrument (Applied Biosystems, Foster City, CA,
USA) by using the following cycling parameters: after
the first step at 95C for 10 min, 40 cycles of denaturation
at 92C for 15 s and extension at 60C for 1 min. Genomic
DNA (20 ng/ul) was amplified in a total volume of 10ul
containing 1x Amplification Master Mix (Applied Bio-
systems, Foster City, CA, USA) and 1x probe. Genotypes
were analysed by using the allelic discrimination func-
tion of the system (Table 2). There was no statistically
significant difference between minor and major CRHR1
genotype with sociodemographic characteristics.
Statistics
Student’s t-test was used to compare patients and age
and gender matched general population EST-Q scores
and determine the associations with clinical or sociode-
mographic factors. All continuous variables were con-
trolled for normality using Shapiro-Wilk’s W test.
Logistic regression analysis was performed to study the
association of CRHR1 genotype and EST-Q scores and
calculate odds ratios (OR). EST-Q scores were used as
indicator variables characterizing whether the individual
possesses the emotional disturbances or not according
to the cut-off values. In the SNP analysis we chose be-
tween additive/dominant/recessive model based on the
AIC (Akaike information criterion) of the unadjusted
model (recessive model – minor allele homozygote,
Table 1 Characteristics of aSAH, complications and clinical
outcome
Characteristic N (%)
Male 37 (30%)
Female 88 (70%)
Hunt Hess score
1 17 (14%)
2 66 (53%)
3 23 (18%)
4 14 (11%)
5 5 (4%)
Aneurysm location
ICA 40 (32%)
AcomA 44 (35%)
MCA 22 (18%)
ACA 8 (6%)
BA 9 (7%)
VA 2 (2%)
Intracerebral haemorrhage 22 (18%)
Symptomatic vasospasm 34 (27%)
Ischemic lesions on CT 25 (20%)
Hydrocephalus
acute 43 (34%)
chronic 14a (11%)
Modified Rankin Score
0 4 (3%)
1 7 (6%)
2 57 (46%)
3 49 (39%)
4 8 (6%)
Abbreviations: ICA internal carotid artery, AcomA anterior communicating
artery, MCA middle cerebral artery, ACA anterior cerebral artery, BA basilar
artery, VA vertebral artery, CT computer tomography. aThese 14 patients
required ventriculoperitoneal shunting after aSAH
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dominant model – major allele homozygote, additive
model – OR for heterozygotes, which is multiplied in
case of minor allele addition (minor homozygote – OR x
OR)). When recessive genotype was rare (3 or less pa-
tients) then dominant model was preferred. Results were
considered significant if p < 0.05. The p-values that sur-
vived the Bonferroni correction are marked in bold.
Pearson’s correlation was used to asses internal correl-
ation in EST-Q scales and logistic regression analysis
was used to describe the influence of CRHR1 genotype
(frequency of minor alleles) and patient factors on fa-
tigue. Statistical analysis was performed with Stata 14.2
(StataCorp LLC) and SPSS 24 (IBM). Statistical analysis
was performed with R (The R Foundation) and Stata
14.2 (StataCorp LLC).
Results
The average age at follow-up was 58 years (SD = 12,
range 26–82). 78% (n = 97) of the patients were living
with family or someone else. 67% (n = 84) had hyperten-
sion, 14% (n = 18) joint pain or rheumatoid arthritis, 7%
(n = 9) had diabetes and 2% (n = 3) reported myocardial
infarction. 24% (n = 30) of the patients received meto-
prolol, 17% (n = 21) amlodipine, 11% (n = 14) ramipril,
8% (n = 10) telmisartan, 6% (n = 8) enalapril, and 6%
(n = 8) received perindopril/indapamide. Other medica-
tions were less common. 41% (n = 51) of the patients re-
quired help in everyday life. 24% (n = 30) of the patients
saw a psychologist or psychiatrist and 38% (n = 47) used
antidepressants or similar medication at some point after
aSAH.
Of the patients, 55% (n = 68) had a mRS score of 0–2
and 39% (n = 48) had a score of 3. Worse mRS score was
associated with female gender (2.5 (SD = 0.8) vs 2.1
(SD = 0.8), p = 0.019) and requiring more daily help (3.1
(SD = 0.5) vs 2.0 (SD = 0.7), p < 0.001).
Emotional outcome scores
Patients scored significantly worse on all EST-Q scales
compared to the general population (Table 3). Female
gender was associated with worse EST-Q scores: depres-
sion (mean 9 (SD = 6.8) vs 5.6 (SD = 4.7), p = 0.006), anx-
iety (mean 9.2 (SD = 5.8) vs 6.7 (SD = 4.9), p = 0.021),
agoraphobia-panic (mean 3.8 (SD = 4.3) vs 1.2 (SD = 2),
p < 0.001), fatigue (mean 7.2 (SD = 4.2) vs 5.4 (SD = 4),
p = 0.03), and insomnia (mean 5.1 (SD = 3.3) vs 3.7 (SD =
3.6), p = 0.04). A worse fatigue score was associated with
having hypertension (mean 7.5 (SD ± 4.2) vs 4.9 (SD ±
3.6), p < 0.001) and having joint pains (mean 8.6 (SD ±
3.4) vs 6.4 (SD ± 4.3), p = 0.021). Taking amlodipine was
associated with a worse depression score (10.7 (SD ± 6.9)
vs mean 7.5 (SD ± 6.3), p = 0.035).
aSAH patients had a high prevalence of those scoring
above the cut-off values for emotional disturbances com-
pared to the general population, with fatigue and insom-
nia being the most common problems presenting in
around half of the patients (Fig. 2). About one third of
the patients had higher than cut-off scores demonstrat-
ing depression (29%, n = 36) and anxiety (30%, n = 38).
15% of patients (n = 19) had higher than cut-off values
on agoraphobia-panic scale. 14% (n = 18) of aSAH pa-
tients had frequent thoughts of death or suicide (ranging
from sometimes to constant) compared to 3% (n = 126)
in the general population (p < 0.001).
Association of genotype with EST-Q outcomes
In regression analysis we explored the association of
CRHR1 genotype with emotional disorder symptoms
(Table 4). The results remained significant after adjust-
ment for gender, neurological state at admission (HH),
patient age and time from aSAH to evaluation. Effect of
Rs110402 on fatigue remained statistically significant
after Bonferroni correction for multiple comparisons.
Table 2 CRHR1 allele distribution (n = 125)
SNP Genotype (n) Minor allele (n) Major allele (n)
Rs7209436 C/C (34) C/T (69) T/T (22) T (91) C (103)
Rs110402 G/G (29) A/G (68) A/A (28) A (96) G (97)
Rs242924 G/G (31) G/T (67) T/T (27) T (94) G (98)
Abbreviations: CRHR1 corticotropin-releasing hormone receptor 1, SNPsingle nucleotide polymorphism
Table 3 EST-Q scores among aSAH patients (n = 125) and age and gender matched general population (n = 3923)
EST-Q scales aSAH mean, n = 125 aSAH SD Population mean, n = 3923 Population SD p-value
Depression 8 6.5 4.3 5.4 < 0.001
Anxiety 8.5 5.6 4.5 4.4 < 0.001
Agoraphobia-Panic 3 3.9 0.9 2.6 < 0.001
Fatigue 6.7 4.2 3.1 2.7 < 0.001
Insomnia 4.7 3.4 3.2 3 < 0.001
Abbreviations: SD standard deviation, p p-value
Vetkas et al. BMC Neurology          (2020) 20:142 Page 4 of 9
Rs110402 minor genotype carriers had a reduced risk
of depression (OR = 0.5, 95% CI, 0.28–0.92, p = 0.027) in
the additive model. Among patients with the minor
Rs110402 alleles prevalence of depression was close to
the general population (14%) and much lower than in
patients with the major genotype (41%) (Fig. 3).
CRHR1 minor alleles (Rs7209436, Rs110402,
Rs242924) had a protective effect against developing fa-
tigue (OR = 0.22–0.46, p < 0.05) in additive and recessive
models. Prevalence of fatigue was 62% vs 25% in major
and minor allele homozygotes of Rs110402, respectively
(Fig. 3). TAT haplotype, formed by the three minor al-
leles, was associated with a significant protective effect
against fatigue (OR = 0.26, 95% CI, 0.08–0.81, p = 0.021)
in the additive model.
Rs242939 minor allele had a protective effect against
insomnia when adjusted for gender, Hunt Hess score,
patient age and time of evaluation from aSAH (OR* =
0.43, 95% CI, 0.18–1.02, p* = 0.057) in the additive
model (Table 4).
Internal correlation and factors influencing fatigue
Almost half of aSAH patients had higher than cut-off
EST-Q scores indicating fatigue (45%; n = 56) and in-
somnia (41%; n = 51). Mental health disorders, as diag-
nosed by EST-Q cut-off values, were significantly
correlated with each other (Table 5). There was a mod-
erate correlation between mRS and EST-Q scales, with
higher values for fatigue and depression. Rs110402 was
significantly correlated to fatigue and depression and
Rs7209436 to fatigue.
We performed a multiple regression analysis for fa-
tigue due to its reported association with anxiety and de-
pression. The best model for fatigue included anxiety,
mRS and Rs110402 genotype (number of minor alleles)
with a R2 = 0.34, p < 0.001 (Table 6). In a separate ana-
lysis, with insomnia entered instead of mRS, the model
still had good explanatory value, but R2 decreased to
0.31, p < 0.001. Sociodemographic factors and comor-
bidities were not associated with fatigue in multiple re-
gression analysis.
Discussion
We describe an association of CRHR1 genotype with
mental health after aSAH. Multiple logistic regression
analysis showed that corticotropin-releasing hormone
receptor 1 genotype (Rs7209436, Rs110402, Rs242924)
was associated with mental health disorders measured
with EST-Q. Rs110402 minor allele decreased the risk of
depression (OR = 0.25, p = 0.027 for minor allele homo-
zygotes). Rs110402, Rs242924 and Rs7209436 minor al-
leles and TAT-haplotype formed by them were
protective against developing fatigue (OR = 0.22–0.46,
p < 0.05). Only association of Rs110402 with fatigue
Fig. 2 Prevalence (%) of emotional disorders according to cut-off
values among aSAH patients (n = 125) and age and gender matched
general population (n = 3923) based on the EST-Q cut-off scores
(all p < 0.001)
Table 4 Influence of genotype on EST-Q outcomes (only statistically significant results are reported)
SNP Allele Model OR 95% CI p OR* 95% CI* p*
Depression
Rs110402 Minor Additive 0.50 0.28–0.92 0.027 0.50 0.26–0.94 0.032
Fatigue
Rs110402 Minor Additive 0.46 0.26–0.8 0.006 0.48 0.27–0.85 0.012
Rs7209436 Minor Recessive 0.22 0.07–0.69 0.009 0.23 0.07–0.75 0.015
Rs242924 Minor Recessive 0.35 0.14–0.9 0.030 0.37 0.14–0.98 0.044
TAT-haplotype Minor Additive 0.26 0.08–0.81 0.021 0.27 0.08–0.88 0.030
Insomnia
Rs242939 Minor Additive 0.43 0.18–1.02 0.057 0.38 0.15–0.96 0.042
Abbreviations: OR odds ratio, CI confidence interval. P-values that are adjusted for gender, Hunt Hess score, patient age and time of evaluation from aSAH are
marked with *. P-values that survived the Bonferroni correction are marked with bold
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remained statistically significant after Bonferroni correc-
tion (OR = 0.21, p = 0.006 for minor allele homozygotes).
Rs242939 minor genotype was associated with a lower
prevalence of insomnia in the adjusted model.
Our study shows that aSAH patients frequently experi-
ence long-term mental health disturbances. Emotional
disturbances have been reported after stroke. A recent
study described similarities among patient perceived
outcomes in quality of life components after different
types of stroke (ischemic stroke, intracerebral
hematoma, and SAH) [22]. These patients, similar to
aSAH, experience a severe life-changing event, which re-
quires habituation and acquiring a new social role. Post-
stroke depression occurs in up to 33% and anxiety in up
to 25% of cases, with reported associations between
them [23, 24]. In our study almost 1/3 of aSAH patients
scored above the cut-off values of EST-Q indicating de-
pression and anxiety. 20% (n = 25) showed a coexistence
of the two conditions. Depression and anxiety were
moderately correlated with each other (Pearson’s r =
0.54, p < 0.001) and presented more often among
women.
Almost half of the patients in our study (45%) scored
above the cut-off value for fatigue. Fatigue is considered
to be the most common complaint after stroke and it
occurs in up to 50% of cases [25]. Fatigue could be de-
fined as “a state characterized by weariness unrelated to
previous exertion levels and usually not ameliorated by
rest” [26]. Fatigue is considered to be a separate entity
from other mental health disorders and its occurrence
after neurological diseases is more frequent than would
be expected based on age and disability [27]. Among
younger patients with stroke, fatigue predicts a worse
health-related quality of life than neurologic dysfunction
[28]. Fatigue has a detrimental effect on quality of life by
restricting everyday activities and it can persist due to a
state of mental exhaustion from having to deal with pro-
cesses of rehabilitation and adaptation. Poststroke fa-
tigue has been associated with anxiety and depression,
but it can occur separately from them [29]. Fatigue can
persist after successful treatment of major depression
and it requires distinct interventions [30]. In our study
fatigue showed a moderate correlation to anxiety (Pear-
son’s r = 0.49, p < 0.001) and depression (r = 0.42, p <
0.001). In a multiple regression model, 34% of variance
in fatigue was best explained by anxiety, mRS score and
Rs110402 genotype, p < 0.001). This implies that fatigue
is related both to physical and mental complaints of the
patients and requires a multidisciplinary management.
We describe a significant number of patients reporting
thoughts of death and suicide (14%, n= 18), which reflects
on the extent of their emotional problem. Suicidality was not
associated with CRHR1 genotype in our study. Patients also
had a high prevalence of agoraphobia-panic complaints and
twice as much sleep problems as the general population.
70% of the patients in our study were female and female gen-
der was associated with worse EST-Q scores.
The neural events of mental health disturbances after
aSAH, measured in this study with EST-Q, remain
largely unknown. Hormonal changes have been pro-
posed as a cause, but studies reported varying results
Table 5 Correlations between EST-Q scales and CRHR1 genotype in aSAH patients (n = 125). *p < 0.001; **p < 0.01; ***p < 0.05
Variables Fatigue Depression Anxiety Panic-Agorophobia Insomnia mRS Rs110402 Rs7209436
Depression 0.42*
Anxiety 0.49* 0.54*
Panic-Agorophobia 0.34* 0.47* 0.59*
Insomnia 0.33* 0.33* 0.34* 0.28**
mRS 0.4** 0.34** 0.29** 0.28** 0.23**
Rs110402 −0.25*** −0.20*** −0.12 −0.06 −0.06 −0.14
Rs7209436 −0.23*** − 0.15 −0.12 − 0.06 −0.1 − 0.14 0.89***
Rs242924 −0.15 −0.15 − 0.07 −0.01 − 0.06 −0.16 0. 86*** 0.9***
Fig. 3 Prevalence of fatigue and depression based on cut-off values
in aSAH patients (n = 125) according to Rs110402 to genotype. MM
– homozygote for major allele, mM – heterozygote, mm –
homozygote for minor allele
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[31]. Coping strategies and premorbid psychiatric history
could affect the long-term outcome of patients [32], but
are hard to study retrospectively. It is possible that pa-
tients have a psychological reaction to a sudden trau-
matic event and live with a recurrent fear of rebleeding
that affects their emotional well-being [6]. Patients might
be stigmatised by the disease or there is a distinct neuro-
biological predisposition for psychological maladaptation
after aSAH. Understanding that a person with an intrin-
sic vulnerability is at more risk of developing a mental
illness or an inadequate psychological reaction to a
stressful life event is well acknowledged in the psychi-
atric community [33].
It is unknown whether the studied SNP-s are func-
tional or they are in linkage disequilibrium with other
regions, but it has been previously reported that CRHR1
genotype is related to formation of major depression
after stressful life events and could moderate cortisol re-
activity to stress [12, 13]. In a multilocus genetic profile
score study, CRHR1 together with other HPA genes has
been shown to interact with chronic stress moderating
diurnal cortisol slope and predicting fatigue [34]. CRHR1
genotype has been associated with PTSD and depression
symptoms in survivors of post-surgical intensive care
unit treatment [35]. Cortisol dysbalance occurs in critical
illness patients, with a possible insufficiency after aSAH
[36]. Corticosteroid administration was associated with a
decreased frequency of post intensive care PTSD symp-
toms after major surgery [37].
Emotional health disturbances after aSAH are reported
rather unhomogenously. Some studies describe the pa-
tients as being depressed, having anxiety, chronically fa-
tigued or experiencing PTSD symptoms. Psychiatric
disturbances have a certain overlapping and a more uni-
form diagnostic strategy is required. There are few gen-
etic studies related to outcomes after aSAH and their
results have been inconclusive. One of the shortcomings
is that outcomes were mostly measured with general
scoring systems (Glasgow Outcome Scale, modified Ran-
kin Scale), which are clinically relevant, but do not re-
flect on the entire state of patients recovery [5]. Health
related quality of life was assessed separately in the same
group of aneurysmal SAH patients using SF-36 ques-
tionnaire and it was reduced in all domains including
mental health, where it was positively associated with
minor CRHR1 genotype [7]. The strength of the current
study is that patients were characterised using a sensitive
assessment tool that showed an array of psychological symp-
toms with high prevalence in post-aSAH patients, including
suicidal thoughts. To the best of our knowledge, this is the
first study reporting a genetic association with specific men-
tal health disturbances after aSAH. The different emotional
problems that aSAH patients experience could be intercon-
nected, but they most likely require distinct neurocognitive
interventions and counselling. Mental health disturbances
could interfere with patients returning to work and increase
the disease burden [38, 39]. We describe a neurobiological
predisposition for development of depression and fatigue
after aSAH which could help in selecting patients at risk and
potentially guiding their therapy.
Limitation of the study
Our study was a retrospective design and included 125
patients, due to this our results in SNP analysis might be
underpowered to draw certain conclusions. Despite
mental health diagnosis being extractable from the na-
tional database, we don’t know the full extent of previ-
ous emotional problems in our patient group. Cultural
factors could also influence outcomes. We lack informa-
tion regarding the cognitive profile of the patients, but
none of them had severe disabilities when interviewed.
Our findings need to be validated in a larger prospective
cohort and further studies are required to determine the
functional consequences of CRHR1 genotype variability.
Conclusions
Results of our study suggest that prevalence of long-term emo-
tional health disorders after aSAH is high with depression and
anxiety presenting in one-third of patients. Fatigue is the most
common problem and it is influenced both by mental and
physical state of the patients. CRHR1 minor genotype was asso-
ciated with less fatigue and depression symptoms after aSAH.
The association with CRHR1 could be due to its role in the
HPA-system response to stress and predisposition of patients
to emotional problems after adverse life-events. New and im-
proved biomarkers are needed to predict, diagnose and treat
the long-term consequences of aSAH. Such biomarkers could
help identify patients who would benefit from early neuro-
psychological rehabilitation and decrease the disease burden.
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